{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:49:59Z","timestamp":1789235399120,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Kidney J"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1093\/ckj\/sfw039","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T02:13:04Z","timestamp":1464660784000},"page":"580-582","source":"Crossref","is-referenced-by-count":13,"title":["Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone: Table\u00a01."],"prefix":"10.1093","volume":"9","author":[{"given":"Melissa","family":"Nataatmadja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakshinamurthy","family":"Divi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,5,30]]},"reference":[{"key":"2016072209330259000_9.4.580.1","unstructured":"NPS MedicineWise. Opioid abuse: will tamper-proof oxycodone help? http:\/\/www.nps.org.au\/publications\/health-professional\/health-news-evidence\/2014\/tamper-proof-oxycodone ."},{"key":"2016072209330259000_9.4.580.2","unstructured":"Mundipharma. Product information: Oxycontin modified release tablets. http:\/\/secure.healthlinks.net.au\/content\/mf\/pi.cfm?product=mfpoxycr"},{"key":"2016072209330259000_9.4.580.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.06.006"},{"key":"2016072209330259000_9.4.580.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020528"},{"key":"2016072209330259000_9.4.580.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.07.004"},{"key":"2016072209330259000_9.4.580.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312353"},{"key":"2016072209330259000_9.4.580.7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12718"},{"key":"2016072209330259000_9.4.580.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp053024"},{"key":"2016072209330259000_9.4.580.9","unstructured":"U.S. Food and Drug Administration. FDA approves abuse-deterrant labelling for reformulated OxyContin. FDA News Release 2013. http:\/\/fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm348252.htm (15 February 2015, date last accessed)"},{"key":"2016072209330259000_9.4.580.10","unstructured":"U.S. Food and Drug Administration. FDA warns about serious blood disorder resulting from misuse of Opana ER. Drug safety and availability 2012. http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm322432.htm (15 February 2015, date last accessed)"},{"key":"2016072209330259000_9.4.580.11","first-page":"1","article-title":"Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse\u2014Tennessee, 2012","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2016072209330259000_9.4.580.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-503904"},{"key":"2016072209330259000_9.4.580.13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.01.015"},{"key":"2016072209330259000_9.4.580.14","doi-asserted-by":"crossref","unstructured":"Kapila A , Chhabra L , Chaubey VK et al . Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users. BMJ Case Rep 2014. pii: bcr2013203122. doi: 10.1136\/bcr-2013-203122.","DOI":"10.1136\/bcr-2013-203122"},{"key":"2016072209330259000_9.4.580.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2014.01.058"},{"key":"2016072209330259000_9.4.580.16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23720"},{"key":"2016072209330259000_9.4.580.17","first-page":"61","article-title":"Myelotoxicity of high-molecular-weight poly(ethylene oxide) [in Russian]","volume":"67","author":"Karpova","year":"2004","journal-title":"Eksp Klin Farmakol"},{"key":"2016072209330259000_9.4.580.18","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.01125"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/9\/4\/580\/9573017\/sfw039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T18:07:28Z","timestamp":1503598048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article-lookup\/doi\/10.1093\/ckj\/sfw039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,30]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,7,22]]},"published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1093\/ckj\/sfw039"],"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfw039","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,30]]}}}